刘晓聪,林辛辛,张新禄,修建成

• 1:南方医科大学第一临床医学院
• 2:南方医科大学南方医院心内科

摘要(Abstract)：

三尖瓣反流作为一种高发病率疾病，既往一直被忽视。越来越多的研究表明，中重度三尖瓣反流并不是一种良性疾病，多数患者因手术风险高而只能采取药物姑息治疗，经导管三尖瓣反流介入治疗或是一种新的机遇与挑战。本文就目前经导管三尖瓣反流介入治疗的方式与设备进行综述。

关键词(KeyWords)： 三尖瓣反流;介入治疗;经导管干预

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81974266、81800371）;; 广东省科技厅创新人才培养专项（109268542061）

作者(Author): 刘晓聪,林辛辛,张新禄,修建成

参考文献(References)：

• [1] Demir OM, Regazzoli D, Mangieri A, et al. Transcatheter tricuspid valve replacement:principles and design[J]. Front Cardiovasc Med, 2018, 5:129.
• [2] Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation(the Framingham Heart Study)[J]. Am J Cardiol, 1999, 83(6):897-902.
• [3] Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction[J]. Circulation, 2019,140(3):196-206.
• [4] Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease[J]. J Thorac Cardiovasc Surg, 2006,132(6):1258-1261.
• [5] Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery[J]. J Am Coll Cardiol,2017, 70(24):2953-2960.
• [6] Ton-Nu TT, Levine RA, Handschumacher MD, et al. Geometric determinants of functional tricuspid regurgitation:insights from3-dimensional echocardiography[J]. Circulation, 2006, 114(2):143-149.
• [7] Lama P, Tamang BK, Kulkarni J. Morphometry and aberrant morphology of the adult human tricuspid valve leafl ets[J]. Anat Sci Int, 2016, 91(2):143-150.
• [8] Dahou A, Levin D, Reisman M, et al. Anatomy and physiology of the tricuspid valve[J]. JACC Cardiovasc Imaging, 2019, 12(3):458-468.
• [9] Mahmood F, Kim H, Chaudary B, et al. Tricuspid a n n u la r geometry:a three-dimensional transesophageal echocardiographic study[J]. J Cardiothorac Vasc Anesth,2013, 27(4):639-646.
• [10] Rogers JH, Bolling SF. The tricuspid valve:current perspective and evolving management of tricuspid regurgitation[J]. Circulation,2009, 119(20):2718-2725.
• [11] Sanfi lippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement as a consequence of atrial fi brillation. A prospective echocardiographic study[J]. Circulation, 1990. 82(3):792-797.
• [12] Mutlak D, Lessick J, Reisner SA, et al. Echocardiographybased spectrum of severe tricuspid regurgitation:the frequency of apparently idiopathic tricuspid regurgitation[J]. J Am Soc Echocardiogr, 2007, 20(4):405-408.
• [13] Zhou X, Otsuji Y, Yoshifuku S, et al. Impact of atrial fi brillation on t ricuspid and mit ral ann ular dilatation and valvular regurgitation[J]. Circ J, 2002. 66(10):913-916.
• [14] Adler DS. Non-functional tricuspid valve disease[J]. Ann Cardiothorac Surg, 2017, 6(3):204-213.
• [15] Schofer J, Bijuklic K, Tiburtius C, et al. First-in-human transcatheter tricuspid valve repair in a patient with severely regurgitant tricuspid valve[J]. J Am Coll Cardiol, 2015, 65(12):1190-1195.
• [16] Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty:SCOUT trial 30-day results[J]. J Am Coll Cardiol, 2017, 69(14):1795-1806.
• [17] Latib A, Agricola E, Pozzoli A, et al. First-in-man implantation of a tricuspid annular remodeling device for functional tricuspid regurgitation[J]. JACC Cardiovasc Interv, 2015, 8(13):e211-e214.
• [18] Calen C, Taramasso M, Guidotti A, et al. Successful Tricinch-inTricinch transcatheter tricuspid valve repair[J]. JACC Cardiovasc Interv, 2017, 10(8):e75-e77.
• [19] Carrel T, Eberle B. When feasibility does not mean clinical success:early failure of a percutaneous tricuspid reduction system[J]. J Thorac Cardiovasc Surg, 2020, 159(2):e109-e111.
• [20] Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions:landscape, challenges, and future directions[J]. J Am Coll Cardiol, 2018, 71(25):2935-2956.
• [21] Kuwata S, Taramasso M, Nietlispach F, et al. Transcatheter tricuspid valve repair toward a surgical standard:first-in-man report of direct annuloplasty with a cardioband device to treat severe functional tricuspid regurgitation[J]. Eur Heart J, 2017,38(16):1261.
• [22] Nickenig G, Weber M, Schueler R, et al. 6-Month outcomes of tricuspid valve reconstruction f or patients with severe tricuspid regurgitation[J]. J Am Coll Cardiol, 2019, 73(15):1905-1915.
• [23] Curio J, Demir OM, Pagnesi M, et al. Update on the current landscape of transcatheter options for tricuspid regurgitation treatment[J]. Interv Cardiol, 2019, 14(2):54-61.
• [24] Khan JM, Rogers T, Schenke WH, et al. Transcatheter pledgetassisted suture tricuspid annuloplasty(PASTA)to create a doubleorifice valve[J]. Catheter Cardiovasc Interv, 2018, 92(3):E175-E184.
• [25] Greenbaum AB, Khan JM, Rogers T, et al. First-in-human transcatheter pledget-assisted suture tricuspid annuloplasty for severe tricuspid insufficiency[J]. Catheter Cardiovasc Interv, 2021, 97(1):E130-E134.
• [26] Rogers JH, Boyd WD, Bolling SF. Tricuspid annuloplasty with the Millipede ring[J]. Prog Cardiovasc Dis, 2019, 62(6):486-487.
• [27] Rogers T, Ratnayaka K, Sonmez M, et al. Transatrial intrapericardial tricuspid annuloplasty[J]. JACC Cardiovasc Interv,2015, 8(3):483-491.
• [28] Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention:mid-term results from the international TriValve registry[J]. JACC Cardiovasc Interv, 2019, 12(2):155-165.
• [29] Mehr M, Taramasso M, Besler C, et al. 1-Year outcomes after edgeto-edge valve repair for symptomatic tricuspid regurgitation:results from the TriValve registry[J]. JACC Cardiovasc Interv, 2019, 12(15):1451-1461.
• [30] Besler C, Orban M, Rommel KP, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair[J].JACC Cardiovasc Interv, 2018, 11(12):1119-1128.
• [31] Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation:6-month outcomes of the TRILUMINATE single-arm study[J]. Lancet, 2019, 394(10213):2002-2011.
• [32] Santalo-Corcoy M, Asmarats L, Li CH, et al. Catheter-based treatment of tricuspid regurgitation:state of the art[J]. Ann Transl Med, 2020, 8(15):964.
• [33] Perlman G, Praz F, Puri R, et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation:1-year clinical and echocardiographic results[J]. JACC Cardiovasc Interv, 2017, 10(19):1994-2003.
• [34] Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation:insights from the fi rstin-human experience[J]. JACC Cardiovasc Interv, 2019, 12(15):1438-1447.
• [35] Praz F, Spargias K, Chrissoheris M, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation:a multicentre, prospective,observational，fi rst-in-man study[J]. Lancet, 2017, 390(10096):773-780.
• [36] Fam NP, Ho EC, Zahrani M, et al. Transcatheter tricuspid valve repair with the PASCAL system[J]. JACC Cardiovasc Interv,2018, 11(4):407-408.
• [37] Fam NP, Braun D, Bardeleben RSV, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation[J]. JACC Cardiovasc Interv, 2019, 12(24):2488-2495.
• [38] Navia JL, Ka padia S, Elgharably H, et al. Firsti n-human implantations of the navigate bioprosthesis in a severely dilated tricuspid annulus and in a f ailed tricuspid annuloplasty ring[J]. Circ Cardiovasc Interv, 2017, 10(12):e005840.
• [39] Navia JL, Kapadia S, Elgharably H, et al. Transcatheter tricuspid valve implantation of navigate bioprosthesis in a preclinical model[J]. JACC Basic Transl Sci, 2018, 3(1):67-79.
• [40] Hahn RT, Kodali S, Fam N, et al. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation[J]. JACC Cardiovasc Interv, 2020, 13(21):2482-2493.
• [41] Elgharably H, Harb SC, Kapadia S, et al. Transcatheter innovations in tricuspid regurgitation:Navigate[J]. Prog Cardiovasc Dis,2019, 62(6):493-495.
• [42] Lu F, Qiao F, Lv Y, et al. A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model[J]. Int J Cardiol, 2020, 319:120-126.
• [43] Lu FL, Ma Y, An Z, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients[J]. JACC Cardiovasc Interv, 2020, 13(13):1614-1616.
• [44] Sun Z, Li H, Zhang Z, et al. Twelve-month outcomes of the LuXValve for transcatheter treatment of severe tricuspid regurgitation[J].Euro Intervention, 2021. 17(10):818-826.
• [45] Lauten A, Ferrari M, Hekmat K, et al. Heterotopic transcatheter tricuspid valve implantation:first-in-man application of a novel approach to tricuspid regurgitation[J]. Eur Heart J, 2011, 32(10):1207-1213.
• [46] Lauten A, Figulla HR, Unbehaun A, et al. Interventional treatment of severe tricuspid regurgitation:early clinical experience in a multicenter, observational，fi rst-in-man study[J]. Cir Cardiovasc Interv, 2018, 11(2):e006061.
• [47]葛均波院士完成亚洲首例经皮异位三尖瓣植入手术[J].上海医药，2019, 40(13):39.